Why The Price Surged Over 40% Today


Petros Pharmaceuticals Inc (NASDAQ: PTPI) stock price rose more than 40% in intraday trading today. That is why. Petros Pharmaceuticals Inc (NASDAQ: PTPI) stock price rose more than 40% in intraday trading today. Investors are reacting positively to Petros Pharmaceuticals by providing positive results from its preliminary over-the-counter (OTC) label comprehension study for its erectile dysfunction (ED) drug STENDRA (avanafil), which demonstrate understanding of the messages that are contained therein. These results suggest that the draft drug facts labeling wording as written may be appropriate for submission to the FDA for review for over-the-counter labeling. The Pivotal Label Comprehension Study compiled 453 label comprehension interviews – including a large cohort of people with low health literacy – to determine understanding of the fact label draft about medications for STENDRA. And in summary, the proposed over-the-counter (OTC) labeling was well understood, within the parameters of the study, by the consumers who participated. Over 95% of participants provided correct or acceptable answers to questions assessing understanding of nine primary communication messages. And these included whether STENDRA can be used if a person is taking nitrate medications or does not have erectile dysfunction. Interestingly, understanding among people with low health literacy, although slightly lower than those with higher understanding of health, still demonstrated a high level of understanding. It is estimated that only about 25% of the approximately 30 million men with erectile dysfunction in the United States have received oral therapy for erectile dysfunction. KEY QUOTE: “The results of this label comprehension study help us continue to solidify our plans to apply to the FDA to help expand access to STENDRA beyond the prescription model and, if approved by the FDA, to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the U.S. The move to OTC is one of many approaches we are currently exploring to expand the access to STENDRA. We continue our dedication to men with erectile dysfunction by providing innovative new options to help them obtain this medication safely, securely and discreetly. — Fady Boctor, President and CEO Disclaimer: This content is for informational purposes.Before making any investment, you should do your own analysis.

Leave a Reply

Your email address will not be published.